AQST - Aquestive Therapeutics, Inc.
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.2600 |
| Open | 2.2200 |
| Bid | 2.1500 x 1200 |
| Ask | 2.1700 x 800 |
| Day's Range | 2.1100 - 2.2200 |
| 52 Week Range | 0.6180 - 2.6900 |
| Volume | |
| Avg. Volume | 555,279 |
| Market Cap | 123.029M |
| Beta (5Y Monthly) | 2.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7600 |
| Earnings Date | Jul 31, 2023 - Aug 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.17 |
Fair Value
Related Research
GlobeNewswireAquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
Time to maximum blood concentration (median Tmax) for Anaphylm was 10 minutes with a range of 5 to 20 minutesEarly drug exposure at 10 minutes (partial area under the curve, or pAUC0-10min) for Anaphylm was similar to Auvi-Q® (epinephrine injection) auto-injector 0.3mg and over 4 times higher than epinephrine 0.3mg manual injection, while lower than both EpiPen® (epinephrine) auto-injector 0.3mg and the generic equivalent productPharmacodynamic effects were observed as early as 2 minutes for bot
ZacksIs Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
ZacksAre You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice
Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksBest Momentum Stocks to Buy for May 9th
AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.
Simply Wall St.Aquestive Therapeutics First Quarter 2023 Earnings: Beats Expectations
Aquestive Therapeutics ( NASDAQ:AQST ) First Quarter 2023 Results Key Financial Results Revenue: US$11.1m (down 9.3...
ZacksAquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidanceReaffirms commitment to pursue early market access for Libervant™ (diazepam) Buccal FilmObtains dismissal of outstanding shareholder lawsuitsGenerated $47 million non-dilutive cash in the last 12 monthsHosts investment community conference call on May 3, 2023 WARREN, N.J., May 02, 2023 (GLOBE NEWSWI
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
WARREN, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in two upcoming investor conferences as follows: The JMP Life Sciences Conference: fireside chat at 12:00 pm ET on Monday, May 15th and available to host investor meetingsA.G.P.’s Virt
ZacksAquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Anaphylm™ as the proposed brand name for AQST-109, the Company’s polymer matrix-based epinephrine prodr
- GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
WARREN, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it will report results for first quarter ended March 31, 2023, and provide an update on recent developments in its business after market close on Tuesday, May 2, 2023. Management will host
- Simply Wall St.
There's No Escaping Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Muted Revenues Despite A 63% Share Price Rise
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have had a really impressive month, gaining 63% after a shaky...
- GlobeNewswire
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Liberva
- Thomson Reuters StreetEvents
Q4 2022 Aquestive Therapeutics Inc Earnings Call
Q4 2022 Aquestive Therapeutics Inc Earnings Call
ZacksAquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
Pivotal study for AQST-109 (epinephrine sublingual film) on track to start in third quarter 2023Financial turnaround actions on track including 18% reduction of outstanding debt and the receipt of $20 million of non-dilutive capital in the first quarter of 2023Continues to engage FDA on next steps for Libervant™ (diazepam) Buccal FilmProvides full year 2023 financial outlookHosts investment community conference call on March 8, 2023 WARREN, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Ther
ZacksAssertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth
Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
WARREN, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the Oppenheimer 33rd Annual Healthcare Conference from March 13th to March 15th. The Aquestive team is scheduled to present on March 13 at 4:40 pm ET and will host investor meetings
ZacksAquestive Therapeutics (AQST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Aquestive Therapeutics (AQST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it will report results for fourth quarter ended December 31, 2022, and provide an update on recent developments in its business after market close on Tuesday, March 7, 2023. Management will
- GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
WARREN, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that four late breaking posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of AQST-109 epinephrine sublingual film will be presented at the American Academy of Al
ZacksAssertio (ASRT) to Report Q4 Earnings: What's in the Cards?
On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.
- Simply Wall St.
When Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Aquestive Therapeutics...
- GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant™ (diazepam) Buccal Film accelerated market access Expects preliminary unaudited cash and cash equivalents of approximately $27 million as of December 31, 2022 WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceu